The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial

2014 ◽  
Vol 182 ◽  
pp. 66-70 ◽  
Author(s):  
Gülşah Aynaoğlu Yıldız ◽  
Yavuz Emre Şükür ◽  
Can Ateş ◽  
Ruşen Aytaç
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Embryo Transfer ◽  
Intracytoplasmic Sperm Injection ◽  
Luteal Phase ◽  
Releasing Hormone ◽  
Luteal Phase Support ◽  
Gonadotrophin Releasing Hormone

Comparison of four protocols for luteal phase support in frozen-thawed Embryo transfer cycles: a randomized clinical trial

2016 ◽  
Vol 295 (1) ◽  
pp. 239-246 ◽  
Author(s):  
Afsoon Zarei ◽  
Parastoo Sohail ◽  
Mohammad Ebrahim Parsanezhad ◽  
Saeed Alborzi ◽  
Alamtaj Samsami ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Embryo Transfer ◽  
Luteal Phase ◽  
Luteal Phase Support ◽  
Frozen Thawed Embryo Transfer ◽  
Thawed Embryo Transfer

scholarly journals Effects of multiple doses of gonadotropin-releasing hormone agonist on the luteal-phase support in assisted reproductive cycles: A clinical trial study

2021 ◽  
Author(s):  
Maryam Eftekhar ◽  
Maryam Mirzaei ◽  
Esmat Mangoli ◽  
Yasamin Mehrolhasani
Keyword(s):  
Clinical Trial ◽  
Embryo Transfer ◽  
Gnrh Agonist ◽  
Luteal Phase ◽  
Fertilization Rate ◽  
Gonadotropin Releasing Hormone ◽  
Pregnancy Rates ◽  
Releasing Hormone ◽  
Luteal Phase Support ◽  
Multiple Doses

Background: The effect of adding gonadotropin-releasing hormone (GnRH) agonist on the luteal phase support in assisted reproductive technique (ART) cycles is controversial. Objective: To determine the effects of adding multiple doses of GnRH agonist to the routine luteal phase support on ART cycle outcomes. Materials and Methods: This clinical trial study included 200 participants who underwent the antagonist protocol at the Research and Clinical Center for Infertility, Yazd, Iran, between January and March 2020. Of the 200, 168 cases who met the inclusion criteria were equally divided into two groups – the case and the control groups. Both groups received progesterone in the luteal phase, following which the case group received GnRH agonist subcutaneously (0/1 mg triptorelin) zero, three, and six days after the fresh embryo transfer, while the control group did not receive anything. Finally, chemical and clinical pregnancy rates, number of mature oocytes, fertilization rate, total dose of gonadotropin, and the estradiol level were determined. Results: The baseline characteristics were similar in both groups. No significant difference was observed between embryo transfer cycles. Clinical results showed that differences between the fertilization rate, chemical and clinical pregnancies were not significant. Conclusion: The results showed that receiving multiple doses of GnRH agonist in the luteal phase of ART cycles neither improves embryo implantation nor the pregnancy rates; therefore, further studies are required. Key words: Luteal phase, GnRH agonist, ART, Pregnancy rate.

Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial

2014 ◽  
Vol 30 (12) ◽  
pp. 902-908 ◽  
Author(s):  
Salvatore Gizzo ◽  
Alessandra Andrisani ◽  
Federica Esposito ◽  
Marco Noventa ◽  
Stefania Di Gangi ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Pregnancy Rate ◽  
Randomized Clinical Trial ◽  
Luteal Phase ◽  
Stimulation Protocol ◽  
Luteal Phase Support

scholarly journals Luteal Support and Risk of Ovarian Hyperstimulation in Assisted Reproduction (A Review)

2020 ◽  
Vol 27 (6) ◽  
pp. 136-148
Author(s):  
V. A. Krutova ◽  
A. A. Baklakova
Keyword(s):  
Embryo Transfer ◽  
Intracytoplasmic Sperm Injection ◽  
Luteal Phase ◽  
Gonadotropin Releasing Hormone ◽  
In Vitro Fertilisation ◽  
Ovarian Hyperstimulation ◽  
Luteal Support ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Agonist

Background. Gonadotropin-releasing hormone agonist as an ovulation trigger effectively reduces the ovarian hyperstimulation risk in in vitro fertilisation protocols, at the same time requiring an effective luteal phase support in embryo transfer cycles.Objectives. A review of modern approaches to luteal support after the ovulation trigger switch in in vitro fertilisation/intracytoplasmic sperm injection protocols; assessment of feasibility and safety of gonadotropin-releasing hormone agonist in the post-transfer period.Methods. Literature sources were mined in the PubMed, eLibrary, Web of Science, Cochrane Library, Cyberleninka databases at a depth of 10 years. The query keywords were: gonadotropin-releasing hormone agonist, luteal phase support, ovulation trigger, in vitro fertilisation, ovarian hyperstimulation syndrome.Results. The review included 35 records selected from the 96 analysed total. The analysis reveals a sensible efficiency of gonadotropin-releasing hormone agonist for the luteal phase support, improved success of in vitro fertilisation/intracytoplasmic sperm injection and embryo transfer strategies, improved pregnancy outcomes. Microdosing of chorionic gonadotropin to supplement standard progesterone luteal support also improves the pregnancy outcome rate in assisted reproduction, however, at the risk of late ovarian hyperstimulation syndrome and should be applied with caution.Conclusion. Administration of gonadotropin-releasing hormone agonist for luteal support may improve pregnancy outcomes in in vitro fertilisation/intracytoplasmic sperm injection protocols in patients with the ovarian hyperstimulation risk after the ovulation trigger switch. Nevertheless, further research is necessary into the efficacy and safety of gonadotropin-releasing hormone agonist for luteal support in embryo transfer cycles.

Sign in / Sign up

Export Citation Format

Share Document